FDA Pediatric Cancer Panel: Move Away from Single-Agent Studies

Clinical Trials Advisor
In developing future clinical trials, sponsors should consider whether the drug will be intended for use as a single agent or as part of a combination therapy, said members of the Oncologic Drug Advisory Committee’s pediatric subcommittee, in a meeting last month.

To View This Article:


Subscribe To Clinical Trials Advisor